Extreme Bipolar Androgen Therapy With Darolutamide and Testosterone Cypionate in Patients With Metastatic Castration-Resistant Prostate Cancer (ExBAT Trial)
Latest Information Update: 05 Apr 2024
At a glance
- Drugs Darolutamide (Primary) ; Testosterone cipionate (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Therapeutic Use
- Acronyms ExBAT
- 11 Mar 2024 Planned primary completion date changed from 9 Jun 2021 to 15 Mar 2024.
- 18 Feb 2024 Planned End Date changed from 1 Jun 2025 to 29 Feb 2024.
- 18 Feb 2024 Planned primary completion date changed from 1 Jun 2024 to 9 Jun 2021.